Taipei Medical University

MPT0G211 is a highly selective and sensitive HDAC6 inhibitor and showed significantly higher potency than ACY-1215 and ACY-241, both developed by Celgene. We also confirmed its safety without any toxicity to cardia, respiratory and center neuron system. According to our data, MPT0G211 mesylate is a potent anticancer drug, especially in multiple myeloma, showing 80-100% tumor inhibition effect when combined with current chemotherapy treatment. Moreover, it also can ameliorate cognitive impairments in Alzheimer’s disease animal studies. The well patent protected MPT0G211 has completed the majority of IND (Investigational New Drug) enabling study, only a part of chemical and manufacture control remains. The new developing drug will exclusively license to ATP BioPham, a startup derived from Taipei Medical University. ATP BioPharm now has raised an angel round and acquired tutoring and 1.5M funding supports from Silicon Valley Advantage, an accelerator in USA. MPT0G211 will be submitted to IND application to the US FDA in 2021 and proceeded to phase I clinical trial.

Taipei Medical University

Our team aims at offering the faster and safest T cell therapy for various cancers. Our core technology is a novel virus-free T cell manufacturing platform. This novel approach offers a single-step manufacturing process to obtain high purity (>90%) cancer-specific T cells in 10 days. CTA-01, the CytoArm’s lead product, has encouraging efficacies and safety profiles in in-vitro and in-vivo studies of leukemia. Other developing Armed-T cell products also demonstrated excellent in vivo therapeutic effects for solid tumors and metastatic cancers. Key patents have been filed in multiple countries and granted in Taiwan. Now, we are raising our A fund to scale up the process of CTA-01 and also looking for potential partners to co-develop and move forward to initiate IND-enabling studies.

TAIPEI MEDICAL UNIVERSITY -SHUANG HO HOSPITAL,MINISTRY OF HEALTH AND WELFARE

Shuang Ho Hospital was opened on July 1, 2008. It was commissioned by the Ministry of Health and Welfare to build and operate by Taipei Medical University. It is the country's first BOT hospital and a quasi-medical center. The total number of beds is nearly 1,600. In addition to acute treatment, it also provides in-depth long-term and chronic care services, introduces advanced equipment, and provides a full range of medical services. It is a large-scale hospital in New Taipei City.

Shuang Ho Hospital exhibit precision medicine in the current life at the exhibition.
Precise Prevention-"Wearable Heart Monitoring Index"
For real-time data analysis and health scores such as heart rate, fatigue index, blood pressure and electrocardiogram, it can effectively monitor the physical function index, improve the quality of life and recovery of cardiovascular patients, and can quickly and effectively shorten the inspection time when used in medical services.

Accurate diagnosis-"Using artificial intelligence to generate carotid artery ultrasound report"
The report of the carotid artery ultrasound report is a pain point for every neurologist. It takes a lot of time to repeatedly interpret the ultrasound examination. With the assistance of artificial intelligence, through automatic interpretation technology and automatic generation of examination reports, it reduces the burden of medical staff. Burden, and can improve the consistency and accuracy of the report content.

Precision treatment-"Lung cancer immune checkpoint antagonistic treatment"
Aiming at the only cancer immunotherapy approved by the Ministry of Health and Welfare at this stage, it describes that activation of the immune system in the body can restore the immune system's attack on tumors and eliminate tumor cells.

TAIPEI MEDICAL UNIVERSITY HOSPITAL

Taipei Medical University Hospital (TMUH) was founded in 1976. Currently, TMUH has 3 medical buildings equipped with today's most advanced medical technology and machinery. Our commitment to providing the highest quality patient care can best be exemplified by past recognitions awarded to TMUH; this includes achieving ISO-9002 certification, being named a Class I Teaching Hospital under the category of Regional Hospital, and accredited four times by international healthcare standard organization, the Joint Commission International (JCI). We aim to continue to providing patients with comprehensive, exceptional and holistic healthcare.

TMUH has many specialized centers, such as the Reproductive Medicine Center, Weight Management Center, Kidney Center, Bone and Joint Research Center, Minimally Invasive Surgery center and many other diverse, international and pioneering medical services.

TAIPEI MEDICAL UNIVERSITY ．TAIPEI CANCER CENTER

Taipei Cancer Center at Taipei Medical University is Taiwan’s first cancer center providing comprehensive cancer services including cancer prevention, screening, diagnosis, treatment, long-term follow-up, and consultation.

Our multidisciplinary care team, led by expert cancer physicians includes nurses, pharmacists, nutritionists, social workers, psychologists, and other medical professionals, provides personalized care and treatment plans. The clinicians develop individualized cancer treatments with precision medicine for their patients.

Through the expertise of the internationally recognized Taipei Medical University Translation Research Center, we combine newly developed treatment plans and current therapies to maximize patient outcomes. In addition, the Taipei Cancer Center provides new and effective therapies for difficult-to-treat and late-stage cancer patients.

The Proton Center, to be completed in 2021, will provide fourth generation proton therapy with pencil-beam technology and cone-beam CT navigation. This new radiotherapy technology will greatly enhance the quality of medical care and outcomes for our patients with cancer.

TAIPEI MEDICAL UNIVERSITY ．TAIPEI NEUROSCIENCE INSTITUTE

1. A robot dedicated to minimally invasive cranial and spine procedure
ROSA can be used for any type of neurosurgical procedures requiring image-guided surgical planning and precise visualization of the patient’s anatomy as well s the accurate positioning and handling of instruments. In practice, the device is used for biopsies, SEEG, tumor resection, ICH remove, depth electrode implantation in functional neurosurgery, image-guided open skull procedures, neuroendoscopic procedures and other key-hole procedures.
2.The award winning Exablate Neuro™ delivers up to 1000 ultrasound waves to precisely heat and ablate deep brain targets with no surgical incisions or burr holes. Treatment is guided by MR imaging for patient-specific planning, real-time temperature monitoring as well as immediate confirmation of treatment outcome.

TAIPEI MEDICAL UNIVERSITY HOSPITAL

Distal Radial fractures is one of the most common fractures, accounting up to 17~20% of fractures admitted to the emergency room. Dorsal metaphysis comminution of the distal radius and articular fracture are indicators of distal radius instability. The most popular surgery for patients with distal radial comminuted fractures is open reduction internal fixation with locking Plate and screws. We had using designed 3D printing device to assist fracture reduction and internal fixation, especially the distal radial metaphyseal comminuted fragments. Comparing the results of traditional open fixation surgeries, the use of 3D printing tools with reduction forceps can better restore the inclination of the radial articular surface, the radial height and the consistency of the joint. The printing 3D device made by biocompatible disposable materials can be aseptically prepared at high temperature without deformation, and are almost radiolucent under intraoperative X ray imaging, which will not affect the observation of fracture reduction under X ray. The combination of open internal fixation, pelvic clip and this reduction tool can provide counter force, easy to use and without resident’s assistant. Surgery can be performed with minimal invasive incision and achieve perfect reduction and internal fixation of the distal radius fracture.

Taipei Medical University Hospital

Ted-ICU AI Platform: Through reshaping the smart ICU care model, providing multi-point remote healthcare service, and AI-assisted recommendation, the Ted-ICU AI Platform can predict changes in high-risk conditions and introduce therapy and prevention at an early stage.

Taipei Medical University Hospital

Contactless Biometric Platform is designed to provide contactless, round-the-clock, real-time monitoring of patient vital signs such as heart rate, respiratory rate, facial skin temperature, and bed-exit detection. Medical personnel using this system can interact and provide consultation with patients via videoconferencing. The platform is ideal for use in negative pressure isolation wards and mobile cabin hospitals, offering an effective and safe medical care solution for hospitals where patients with COVID-19 or other highly contagious diseases are treated.

Taipei Medical University Office of Business Development-Technology Commercialization Center

TMU Technology Commercialization Center is primarily responsible for coaching the commercialization of technology developed by the research and development (R&D) teams of TMU departments and cultivating cross-industry talent. This increases the industrial value of R&D from TMU, accelerates the R&D startup cycle, and generates effective industry applications of biomedical translation.